Imperial College London

Dr Nick Powell

Faculty of MedicineDepartment of Metabolism, Digestion and Reproduction

Clinical Reader in Gastroenterology
 
 
 
//

Contact

 

nicholas.powell

 
 
//

Location

 

Norfolk PlaceSt Mary's Campus

//

Summary

 

Summary

Nick is a Clinical Reader and consultant in Gastroenterology. His key clinical and research interests focus on intestinal inflammation in the context of inflammatory bowel diseases (such as ulcerative colitis and Crohn’s disease), but also in gut inflammation resulting from certain treatments, such as immune checkpoint inhibitors.     

His research group focuses on the molecular and cellular mechanisms responsible for mediating chronic intestinal inflammation, and understanding the dialogue between intestinal microbes and host immunity. His lab is also interested in understanding how cell-specific and tissue-specific transcriptional programmes, including cytokine-responsive networks, disclose important information about disease pathogenesis, and how these "molecular signatures" can be harnessed to predict patient outcomes.

He was previously awarded a Wellcome Trust Intermediate Clinical Fellowship (2013-2019).  He completed specialist registrar training in gastroenterology and internal medicine in London (Hammersmith, St Mary’s). He has also been awarded an MSc (Imperial College London) and PhD in immunology (King’s College London). Major funding has been awarded by the Wellcome Trust, MRC and Crohn’s and Colitis UK. Some key publications include; Powell N, et al. Gastroenterology (2015); 149:456-467, Goldberg R, et al. Nature Reviews in Gastroenterology and Hepatology (2015); 12:271-283, Powell N, et al. Immunity (2012); 37:674-84.   

Publications

Journals

Alexander J, Powell N, Teare J, et al., 2021, Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor induced enterocolitis treated with infliximab, Journal for Immunotherapy of Cancer, ISSN:2051-1426

Powell N, 2021, Infliximab is associated with attenuatedimmunogenicity to BNT162b2 and ChAdOx1 nCoV-19SARS-CoV-2 vaccines in patients with IBD, Bmj: British Medical Journal, ISSN:0959-535X

Kennedy NA, Goodhand JR, Bewshea C, et al., 2021, Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab, Gut, Vol:70, ISSN:0017-5749, Pages:865-875

Alexander JL, Moran GW, Gaya DR, et al., 2021, SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement, Lancet Gastroenterology & Hepatology, Vol:6, Pages:218-224

Schroeder J-H, Meissl K, Hromadova D, et al., 2021, T-Bet controls cellularity of intestinal group 3 innate lymphoid cells, Frontiers in Immunology, Vol:11, ISSN:1664-3224, Pages:1-11

More Publications